PHPilar Hernández-Jiménez

Pilar Hernández-Jiménez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pilar Hernández-Jiménez has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Online educational resources for tuberculosis infection screening and treatment in migrants: a national survey.

    by Pilar Hernandez-Jimenez, Sulaimaan Sheikh, Lara Kabalan, Alasdair Frater, Jinming Zhang, Yunfei Long, Heinke Kunst

    Background: Effective tuberculosis infection (TBI) management in migrants depends on patient understanding of infection, its distinction from active disease, and the benefits and risks of preventive treatment. Online educational resources may support this, but their availability, quality and clinical use remain unclear. Methods: A national cross-sectional survey of healthcare professionals involved in TBI screening and treatment of migrants assessed awareness, use, perceived quality and barriers related to online resources. SurveyMonkey platform was used and data was analysed in STATA19. Results: 50 healthcare professionals responded, 48 were involved in TBI care. Availability and quality of online resources were rated ≤3/5 by 39 (78%). Commonly used resources for TBI education 15 (21%) responded there were no adequate resources. When asked if clinicians used educational resources, 14 (28.5%) said “Yes”, 18 (36.7%) “Sometimes”, 9 (18.4%) “Rarely” and 8 (16.3%) “No”. Key barriers for explaining TBI to patients included language differences (32, 64%), limited interpreter availability (31, 62%), and low health literacy (25, 50%). When asked about the interventions to improve TBI outcomes 38 participants responded “Multilingual education materials”, 28 “Education in adverse effects”, 28 “Improve access to interpreters” and 27 “Digital educational tools”. Most respondents 45 (90%) supported a single integrated digital educational tool. Conclusion: Online educational resources supporting TBI care for migrants are limited in quality and inconsistently used. Improved accessibility of educational resources and integration of digital tools may enhance management of TBI care.

  • Open Access

    Granulomatous inflammation in histopathological samples: examining the aetiological spectrum, diagnostic challenges, and future perspectives

    by Pilar Hernández-Jiménez, Mónica Sánchez de la Fuente, Jorge Macedo Pascual, Javier Merino Bustinduy, Antonio González García, Diego Revilla Oliva, Juan María Herrero-Martínez, Paula López-Roa, Ana Belén Enguita Valls, Mikel Mancheño-Losa, et al.

    Granulomas are a distinct chronic response of the immune system to a range of antigenic stimuli. They are formed by an organised, multicellular structure of immune cells working together in a dynam...

  • Open Access

    Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections

    by Eva Benavent, Jaime Lora-Tamayo, Marta Ulldemolins, Paula Pons-Oltra, Matthieu Gregoire, Mikel Mancheño-Losa, Pilar Hernández-Jiménez, M. Ángeles Meléndez-Carmona, Victor Casals, Jason A. Roberts, et al.

    The efficacy, safety, and population pharmacokinetics of a single 1,500 mg dose of dalbavancin as a sequencing treatment for Gram-positive chronic prosthetic joint infections (CPJIs) have not been described. We present an observational, retrospective study conducted in two Spanish hospitals including patients with CPJI caused by Gram-positive bacteria susceptible to dalbavancin managed with two-stage exchange, antibiotic-loaded spacers, and a single 1,500 mg dose of dalbavancin. Follow-up visits included measurement of dalbavancin plasma concentrations. Negative intraoperative cultures at second-stage surgery defined microbiological cure. Population pharmacokinetics and Monte Carlo dosing simulations were used to evaluate whether this dose provided a therapeutic antibiotic exposure defined as the ratio between the area under the unbound concentration curve and the bacteria minimum inhibitory concentration (ƒAUC 0-24h /MIC) ≥ 50 for the entire treatment period. Twenty patients were included, with CPJI mostly caused by coagulase-negative staphylococci (71%). After 11.5 days of intravenous antibiotic therapy (vancomycin, 75%), patients received 1,500 mg of dalbavancin without adverse events. Microbiological cure was 94.7% (median follow-up, 693 days). Dosing simulations suggest that a single 1,500 mg dose of dalbavancin is sufficient for maintaining ƒAUC 0-24h /MIC ≥ 50 for MIC ≤ 0.25 mg/L for 3–4 weeks after administration. A single 1,500 mg dose of dalbavancin combined with antibiotic-loaded spacers may be an effective and safe sequencing treatment for CPJI and provide 3–4 weeks of therapeutic exposure for susceptible microorganisms. Considering dalbavancin’s unique pharmacokinetics, this approach may be considered in the clinical management of CPJI.


  • General Aspects of Treatment of Fracture-Related Infection

    by Cristina Ojeda-Thies, Pilar Hernández-Jiménez, Mikel Mancheño-Losa, Nieves Vanaclocha

  • Open Access

    Periprosthetic Infection of Transfibular Ankle Arthroplasties Managed with Implant Retention: Anatomical Limitations of Surgical Debridement

    by Pilar Hernández-Jiménez, Mikel Mancheño-Losa, María Ángeles Meléndez-Carmona, M Ángela Mellado-Romero, Patricia Brañas, Carlos Lumbreras-Bermejo, Jesús Enrique Vilá Y Rico, Jaime Lora-Tamayo

    Background: Prosthetic ankle infection is an infrequent and rarely explored prosthetic joint infection (PJI). In early infection, the debridement of implants inserted using the transfibular approach has certain peculiarities that pose a diagnostic and therapeutic challenge, the impact of which on infection prognosis is still unknown. Methods: This study prospectively collected all cases of transfibular prosthetic ankle infection at a tertiary hospital between 2014 and 2022, describing their demographic, clinical, microbiological, and management characteristics, along with the outcome over a long follow-up. This cohort was compared with a cohort of infected fibular plates without prostheses implanted in the same period of time. Results: Seven cases of ankle PJI were analysed, all of them implanted using a transfibular approach. They were all early prosthetic infections. The median age was 63 years (range 54–74) with a predominance of women (71.4%), three patients with diabetes (42.9%), and one patient with rheumatoid arthritis (14.3%). The aetiology was predominantly staphylococcal (4 [57.1%] methicillin-susceptible S. aureus and 1 [14.3%] S. epidermidis). All cases were managed with irrigation and debridement limited to the fibular plate, four of which failed (57%). By comparison, eleven cases of infected fibular plates without prostheses implanted were analysed. There were no differences in clinical, microbiological, or therapeutic management characteristics between the groups. Failure among infected fibular plates occurred in only two cases (18%). Conclusions: Debridement of infected transfibular ankle prostheses suggests a worse evolution than would be expected for other joint infections. This could be explained by the nature of the debridement, limited to the fibular component. Further detailed studies of the surgical possibilities in prosthetic ankle infections are necessary to improve the prognosis of these infections, given their impact on joint function.


  • Open Access

    Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review

    by Jaime Lora-Tamayo, Mikel Mancheño-Losa, María Ángeles Meléndez-Carmona, Pilar Hernández-Jiménez, Natividad Benito, Oscar Murillo

    Prosthetic joint infections are considered difficult to treat they needing aggressive surgery and long antimicrobial treatments. However, the exact duration of these therapies has been established empirically. In the last years, several studies have explored the possibility of reducing the length of treatment in this setting, with conflicting results. In this narrative review, we critically appraise the published evidence, considering the different surgical approaches (implant retention [DAIR] and one-step and two-step exchange procedures) separately. In patients managed with DAIR, usually treated for at least 12 weeks, a large, randomized trial failed to show that 6 weeks were non-inferior. However, another randomized clinical trial supports the use of 8 weeks, as long as the surgical conditions are favorable and antibiotics with good antibiofilm activity can be administered. In patients managed with a two-step exchange procedure, usually treated during 6 weeks, a randomized clinical trial showed the efficacy of a 4-week course of antimicrobials. Also, the use of local antibiotics may allow the use of even shorter treatments. Finally, in the case of one-step exchange procedures, there is a trend towards reducing the length of therapy, and the largest randomized clinical trial supports the use of 6 weeks of therapy.


  • Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection

    by Laura Corbella, Mario Fernández-Ruiz, María Ruiz-Ruigómez, Isabel Rodríguez-Goncer, José Tiago Silva, Pilar Hernández-Jiménez, Francisco López-Medrano, Manuel Lizasoain, Jennifer Villa, José María Aguado, et al.

    Purpose To know whether the production of OXA-48 carbapenemase exerts an independent impact on the outcome of Klebsiella pneumoniae infection, once adjusted by clinical syndrome and baseline risk factors. Methods We performed a case-cohort study including 117 infectious episodes due to OXA-48-producing K. pneumoniae (OXA-48-Kp) and 117 episodes due to non-OXA-48-producing strains (non-OXA-48-Kp). Both groups were matched (1:1 ratio) by clinical syndrome (source of infection, preceding invasive procedures and indwelling devices, and associated bacteremia) and hospitalization ward at infection onset. Multivariate Cox regression was used to investigate the association between OXA-48-Kp infection and clinical cure by day 14 (primary outcome) and 30-day all-cause mortality (secondary outcome). Results Both study groups were well balanced regarding underlying conditions and comorbidity burden. Sepsis or septic shock were more frequent in OXA-48-Kp cases than non-OXA-48-Kp controls (41 [35.0%] vs. 17 [14.5%]; P-value < 0.0001). Clinical cure by day 14 was less commonly achieved in OXA-48-Kp cases (49 [41.9%] vs. 95 [81.2%]; P-value < 0.001), whereas 30-day all-cause mortality was higher (33 [28.2%] vs. 18 [15.4%]; P-value = 0.018). Multivariate analysis confirmed that OXA-48-Kp infection was independently associated with the lack of 14-day clinical cure (adjusted hazard ratio [aHR]: 0.45; 95% confidential interval [95%CI]: 0.29–0.70; P-value < 0.0001). A non-significant association was observed for 30-day all-cause mortality (aHR: 1.65; 95%CI: 0.92–2.94; P-value = 0.093). Conclusion Our matched analysis suggests that the production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in K. pneumoniae infection as compared to episodes due to non-carbapenemase-producing strains.


  • Open Access

    Risk Factors and Outcomes for Multidrug Resistant Pseudomonas aeruginosa Infection in Immunocompromised Patients

    by Pilar Hernández-Jiménez, Francisco López-Medrano, Mario Fernández-Ruiz, J. Tiago Silva, Laura Corbella, Rafael San-Juan, Manuel Lizasoain, Jazmín Díaz-Regañón, Esther Viedma, José María Aguado

    Background: Pseudomonas aeruginosa (PSA) infection often occurs in immunocompromised patients, which also face an increased risk of multidrug-resistant (MDR) bacteria. A deeper knowledge of the risk factors for MDR-PSA infection in this patient population may help to choose appropriate empirical antibiotic therapy. Methods: a single-center case-control (1:2) retrospective study that included 48 patients with underlying immunosuppression developing MDR-PSA infection (cases) and 96 patients also immunocompromised that were infected with non-MDR-PSA (controls) was conducted. Both groups were matched by site of infection, clinical features and type of immunosuppression. Risk factors for MDR-PSA were assessed by logistic regression. Clinical outcomes were also compared between both groups. Results: immunosuppression was due to solid cancer in 63 (43.8%) patients, solid organ transplantation in 39 (27.1%), hematological disease in 35 (24.3%) and other causes in 7 (4.9%). Independent risk factors for MDR-PSA infection were diabetes mellitus (odds ratio [OR]: 4.74; 95% confidence interval [CI]: 1.63–13.79; p = 0.004), antibiotic therapy in the previous 3 months (OR: 5.32; 95% CI: 1.93–14.73; p = 0.001), previous MDR-PSA colonization (OR: 42.1; 95% CI: 4.49–394.8; p = 0.001) and septic shock (OR: 3.73; 95% CI: 1.36–10.21; p = 0.010). MDR-PSA cases were less likely to receive adequate empirical therapy (14 [29.2%] vs. 69 [71.9%]; p < 0.001). 30-day clinical improvement was less common in MDR-PSA cases (25 [52.1%] vs. 76 [79.2%]; p = 0.001). Conclusions: diabetes mellitus, previous MDR-PSA colonization, prior receipt of antibiotics and septic shock acted as risk factors for developing MDR-PSA infections in immunocompromised patients, who have a poorer outcome than those infected with non-MDR-PSA strains.


  • Open Access

    Derivation of a score to predict infection due to multidrug-resistant Pseudomonas aeruginosa: a tool for guiding empirical antibiotic treatment

    by Pilar Hernández-Jiménez, Francisco López-Medrano, Mario Fernández-Ruiz, Jose T. Silva, Laura Corbella, Rafael San-Juan, María Ruiz-Ruigómez, Manuel Lizasoain, Isabel Rodríguez-Goncer, Jazmín Díaz-Regañón, et al.


  • Open Access

    Prognostic factors of OXA-48 carbapenemase-producing Klebsiella pneumoniae infection in a tertiary-care Spanish hospital: A retrospective single-center cohort study

    by Laura Corbella, Mario Fernández-Ruiz, María Ruiz-Ruigómez, Isabel Rodríguez-Goncer, José Tiago Silva, Pilar Hernández-Jiménez, Francisco López-Medrano, Manuel Lizasoain, Jennifer Villa, Octavio Carretero, et al.